Although PARP1 inhibition is a promising therapeutic target, no comprehensive study has addressed PARP1's expression characteristics and prognostic role regarding molecular heterogeneity in astrocytomas including GBM. This evidence concerns the gene PARP1 and astrocytoma (excluding glioblastoma).